With the Alzheimer's treatment landscape littered with failed attempts, one small company is taking a radically different approach to fight the disease and is poised to introduce the first viable treatment that slows or even stops it.

Targeting people who are genetically at risk for Alzheimer's, Alzheon’s protocol flushes the disease causing toxins from the brain before they build up and cause memory loss. They are treating the underlying cause of the disease, not the symptoms, which is the failed approach of so many big pharma companies.

Alzheon CEO is Martin Tolar